Zydus Lifesciences received final USFDA approval to manufacture Apalutamide tablets for prostate cancer, following last week’s approval for Eluxadoline tablets for IBS treatment. The stock shows a hold rating with an 18% target price upside. Despite recent approvals, the shares have declined 7% year-to-date.Read More
Gold prices continue to rise as investors treat gold as an investment. Central banks are accumulating gold. Geopolitical risks and inflation concerns drive demand. Analysts predict that gold may reach Rs 1 lakh per 10 grams in the long-term. They recommend a systematic investment approach for investors to benefit from corrections.Read More
India attracts substantial foreign investments as a structural growth story, but to elevate its GDP growth, key reforms in land, labor, and judicial areas are essential. Managing Director of Kotak Mahindra Asset Management, Nilesh Shah, emphasizes the need for bold policy measures to achieve higher growth rates.Read More
Karthik Kumar, Fund Manager, Axis Mutual Fund, highlights his market outlook, with a focus on growth visibility and sector performance. He remains bullish on telecoms, consumer discretionary, healthcare, and tech, while staying cautious on commodity-related sectors and industrials. Despite recent corrections, he notes continued valuation comfort in certain segments, particularly large-cap tech stocks.Read More
Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada.
